Targeted Radiotherapy Improves Survival in Metastatic Prostate Cancer
نویسندگان
چکیده
منابع مشابه
Local Therapy Improves Survival in Metastatic Prostate Cancer.
BACKGROUND Treatment of the primary, termed local therapy (LT), may improve survival in metastatic prostate cancer (mPCa) versus no local therapy (NLT). OBJECTIVE To assess cancer-specific mortality (CSM) after LT versus NLT in mPCa. DESIGN, SETTING, AND PARTICIPANTS Within the Surveillance, Epidemiology and End Results database (2004-2013), 13 692 mPCa patients were treated with LT (radica...
متن کاملSystemic Targeted Alpha Radiotherapy for Cancer
Background: The fundamental principles of internal targeted alpha therapy for cancer were established many decades ago.The high linear energy transfer (LET) of alpha radiation to the targeted cancer cellscauses double strand breaks in DNA. At the same time, the short range radiation spares adjacent normal tissues. This targeted approach complements conventional external beam radiotherapy and ch...
متن کاملOsteoclast-targeted therapy for metastatic prostate cancer
10.2217/14750708.5.1.63 © 20 Bone metastases and skeletal complications are major causes of morbidity in men with prostate cancer. Despite the osteoblastic appearance of bone metastases on imaging studies, patients with bone metastases have elevated markers of bone resorption, indicative of high osteoclast activity. Indeed, increased osteoclast activity is independently associated with higher r...
متن کاملTargeted α-Based Treatment of Metastatic Castration-Resistant Prostate Cancer: Revolutionizing Systemic Radiotherapy?
1843 The Predictive Value of Early Assessment After 1 Cycle of Induction Chemotherapy with F-FDG PET/CT and Diffusion-Weighted MRI for Response to Radical Chemoradiotherapy in Head and Neck Squamous Cell Carcinoma Kee H. Wong, Rafal Panek, Liam Welsh, Dualta Mcquaid, Alex Dunlop, Angela Riddell, Iain Murray, Yong Du, Sue Chua, Dow-Mu Koh, Shreerang Bhide, Chris Nutting, Wim J.G. Oyen, Kevin Har...
متن کاملAbiraterone plus prednisone improves survival in metastatic castration-resistant prostate cancer.
I n essentially just 1 year’s time, we have seen science translated into exciting new therapeutic agents for men with metastatic castration-resistant prostate cancer (CRPC), most recently with the United States Food and Drug Administration (FDA) approval of abiraterone acetate in combination with prednisone. While prostate cancer has been known to be highly responsive to surgical or medical cas...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Oncology Times
سال: 2021
ISSN: 0276-2234
DOI: 10.1097/01.cot.0000765100.56333.8c